A Randomized Double-Blind Placebo-Controlled Active Comparator Phase 2/3

Recruiting

19 years - 99 years

All

Phase N/A

10 participants needed

1 Location

Brief description of study

This study is being done to see if tucatinib with trastuzumab, ramucirumab and paclitaxel works better than ramucirumab and paclitaxel to treat HER2-positive (HER2+) cancer of the gut (stomach or gastroesophageal cancer). This study will also look at what side effects happen when participants take this combination of drugs

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 19 years - 99 years
Gender: All

Male and Female over 18 years of age

Updated on 04 Aug 2024. Study ID: 844367

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Randomized Double-Blind Placebo-Controlled Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab Ramucirumab and Paclitaxel in Subjects With Previously Treated Locally-Advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)

Brief description of study

Eligibility of study

Find a site

Interested in the study